FDA Approved New Size-Adjustable Valve for Children

The device can expand as a child grows, potentially reducing the need for repeat open-heart surgeries.

Updated on Oct. 1, 2026 in Heart Disease

Isometric editorial illustration of a geometric heart valve device with expanding concentric rings, rendered in deep teal and slate blue. — The FDA has approved a new size-adjustable pediatric heart valve designed to expand via balloon catheter as children grow, potentially reducing the need for repeat surgeries. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical technologies effectively improve long-term healthcare outcomes for children?

The FDA has approved the Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. The device, which uses new polymeric material, is designed to accommodate a child's growth through balloon-catheter expansion.

Why it matters

Congenital heart defects affect about 1 in every 100 births in the United States, with approximately 4,200 babies annually needing treatment for pulmonary valve issues. This technology aims to spare these children from the risks associated with multiple repeat open-heart surgeries as they age.

In a clinical study of 62 pediatric patients across 12 U.S. sites, children demonstrated acceptable hemodynamic performance at the six-month follow-up point.

The players

FDA

The federal agency responsible for evaluating the safety and efficacy of medical devices before they reach the market.

Edwards Lifesciences

A medical technology company specializing in artificial heart valves and hemodynamic monitoring.

Autus Valve Technologies Inc.

The medical device developer responsible for creating the size-adjustable valve technology.

The details

The valve utilizes polymeric material for its leaflets, which is designed to resist hardening and breakdown more effectively than traditional animal-derived tissues. Once implanted, the valve starts at a 13-millimeter diameter and can be manually expanded up to 22 millimeters using a balloon catheter as the child grows.

October 1, 2026: The FDA officially approved the Autus Size-Adjustable Valve.
6 months post-implantation: Patients in the clinical study demonstrated acceptable hemodynamic performance.

Health Landscape

The device represents a shift toward materials designed to withstand the long-term biological stressors of pediatric growth, moving away from conventional animal-derived tissue options. It follows the established FDA premarket approval pathway for high-risk medical devices.

For families managing congenital pulmonary valve disease, this device may represent a new option to discuss during consultations regarding surgical planning. Parents should speak with their pediatric cardiologist about whether this technology is appropriate based on their child's specific condition.

The takeaway

This valve offers a path to reducing the frequency of repeat surgeries for children with pulmonary valve disease. Families should maintain regular follow-up appointments with their cardiology team to monitor the long-term performance of implanted devices.